219 related articles for article (PubMed ID: 27455835)
21. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
[TBL] [Abstract][Full Text] [Related]
22. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
[TBL] [Abstract][Full Text] [Related]
23. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
24. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Kumarathurai P; Anholm C; Larsen BS; Olsen RH; Madsbad S; Kristiansen O; Nielsen OW; Haugaard SB; Sajadieh A
Diabetes Care; 2017 Jan; 40(1):117-124. PubMed ID: 27797930
[TBL] [Abstract][Full Text] [Related]
25. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
27. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.
Nielsen R; Jorsal A; Tougaard RS; Rasmussen JJ; Schou M; Videbaek L; Gustafsson I; Faber J; Flyvbjerg A; Wiggers H; Tarnow L; Kistorp C
Diabetes Obes Metab; 2020 Nov; 22(11):2141-2150. PubMed ID: 32627271
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of myocardial performance index for evaluation of left ventricular function during dobutamine stress echocardiography before and after coronary artery bypass grafting.
Hashemi N; Samad BA; Hedman A; Brodin LÅ; Alam M
Echocardiography; 2014 Sep; 31(8):989-95. PubMed ID: 24354348
[TBL] [Abstract][Full Text] [Related]
30. Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).
Wägner AM; Miranda-Calderín G; Ugarte-Lopetegui MA; Marrero-Santiago H; Suárez-Castellano L; López-Madrazo MJ; Alberiche-Ruano MP; Abselam Ahmed N; Alemán C; Castellot-Martín A; Díez Del Pino A; Nóvoa-Mogollón FJ
Diabetes Metab; 2019 Jun; 45(3):268-275. PubMed ID: 30223083
[TBL] [Abstract][Full Text] [Related]
31. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
[TBL] [Abstract][Full Text] [Related]
32. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Li Q; Jia M; Yan Z; Li Q; Sun F; He C; Li Y; Zhou X; Zhang H; Liu X; Bu X; Gao P; He H; Zhao Z; Zhu Z
J Am Heart Assoc; 2021 Jul; 10(14):e020734. PubMed ID: 34250817
[TBL] [Abstract][Full Text] [Related]
33. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
34. Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C; Kumarathurai P; Samkani A; Pedersen LR; Boston RC; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
Diabetes Obes Metab; 2019 Aug; 21(8):2012-2016. PubMed ID: 31050161
[TBL] [Abstract][Full Text] [Related]
35. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
36. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J; Hyötyläinen T; Orešič M; Nyström T
Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
[TBL] [Abstract][Full Text] [Related]
37. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
Mann JFE; Fonseca VA; Poulter NR; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Mosenzon O;
Clin J Am Soc Nephrol; 2020 Apr; 15(4):465-473. PubMed ID: 32132141
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial.
Arruda-Olson AM; Mahoney DW; Nehra A; Leckel M; Pellikka PA
JAMA; 2002 Feb; 287(6):719-25. PubMed ID: 11851538
[TBL] [Abstract][Full Text] [Related]
39. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Read PA; Khan FZ; Heck PM; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2010 Mar; 3(2):195-201. PubMed ID: 20075143
[TBL] [Abstract][Full Text] [Related]
40. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
